Education
About Us
Working with TipRanks
Follow Us
eFFECTOR Therapeutics (EFTR)
OTHER OTC:EFTR
RESEARCH TOOLSreports
Total Valuation
eFFECTOR Therapeutics has a market cap or net worth of $1.41K. The enterprise value is ―.
Market Cap$1.41K
Enterprise Value―
Share Statistics
eFFECTOR Therapeutics has 4,704,409 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,704,409
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
eFFECTOR Therapeutics’s return on equity (ROE) is 6.18 and return on invested capital (ROIC) is -221.30%.
Return on Equity (ROE)6.18
Return on Assets (ROA)-1.74
Return on Invested Capital (ROIC)-221.30%
Return on Capital Employed (ROCE)6.44
Revenue Per Employee0.00
Profits Per Employee-2.56M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of eFFECTOR Therapeutics is -0.71. eFFECTOR Therapeutics’s PEG ratio is >-0.01.
PE Ratio-0.71
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value-4.41
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio>-0.01
Income Statement
In the last 12 months, eFFECTOR Therapeutics had revenue of 0.00 and earned -35.81M in profits. Earnings per share was -16.37.
Revenue0.00
Gross Profit-22.92M
Operating Income-33.84M
Pretax Income-35.81M
Net Income-35.81M
EBITDA-33.73M
Earnings Per Share (EPS)-16.37
Cash Flow
In the last 12 months, operating cash flow was -29.19M and capital expenditures -84.00K, giving a free cash flow of -29.27M billion.
Operating Cash Flow-29.19M
Free Cash Flow-29.27M
Free Cash Flow per Share-6.22
Dividends & Yields
eFFECTOR Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-55.02
52-Week Price Change-89.29%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
eFFECTOR Therapeutics upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateMar 12, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
eFFECTOR Therapeutics as a current ratio of 0.77, with Debt / Equity ratio of 2448.37%
Current Ratio0.77
Quick Ratio0.77
Debt to Market Cap0.80
Net Debt to EBITDA-0.17
Interest Coverage Ratio0.00
Taxes
In the past 12 months, eFFECTOR Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
eFFECTOR Therapeutics EV to EBITDA ratio is -0.93, with an EV/FCF ratio of -1.05.
EV to Sales0.00
EV to EBITDA-0.93
EV to Free Cash Flow-1.05
EV to Operating Cash Flow-1.06
Balance Sheet
eFFECTOR Therapeutics has $25.38M in cash and marketable securities with $20.25M in debt, giving a net cash position of -$5.13M billion.
Cash & Marketable Securities$25.38M
Total Debt$20.25M
Net Cash-$5.13M
Net Cash Per Share-$1.09
Tangible Book Value Per Share-$2.65
Margins
Gross margin is 48.15%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin48.15%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for eFFECTOR Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast38.17%